title: Oxidant stress is increased during treatment of human immunodeficiency virus infection.
abstract: Some diseases and environmental exposures, including those that are risk factors for atherosclerosis, are associated with increased oxidant stress. The objective of this cross-sectional, observational study was to determine whether oxidant stress is increased during human immunodeficiency virus type 1 (HIV-1) infection or its therapy. To quantify oxidant stress, plasma F2 isoprostane (F2-IsoP) concentrations were determined by gas chromatography/mass spectroscopy. A total of 120 subjects were enrolled during routine primary care visits. The median CD4+ T cell count was 341 cells/mm3, the median HIV-1 RNA level was 3.4 log10 copies/mL, and 74% of patients were receiving antiretroviral therapy. Plasma F2-IsoP concentrations were 12-149 pg/mL (median, 31 pg/mL). In univariate analysis, higher F2-IsoP concentrations were associated with lower log10 plasma HIV-1 RNA levels (P=.009) and with efavirenz use (P=.02). Both factors remained associated with plasma F2-IsoP concentrations in multivariate analysis. Oxidant stress associated with therapeutic control of viral replication may have important implications for long-term complications of antiretroviral therapy.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA.
authors.forename: Todd
authors.initials: T
authors.lastname: Hulgan
authors.forename: Jason
authors.initials: J
authors.lastname: Morrow
authors.forename: Richard T
authors.initials: RT
authors.lastname: D'Aquila
authors.forename: Stephen
authors.initials: S
authors.lastname: Raffanti
authors.forename: Michael
authors.initials: M
authors.lastname: Morgan
authors.forename: Peter
authors.initials: P
authors.lastname: Rebeiro
authors.forename: David W
authors.initials: DW
authors.lastname: Haas
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D028441:F2-Isoprostanes / Q000097:blood*; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D015497:HIV-1; D006801:Humans; D008297:Male; D016877:Oxidants / Q000378:metabolism; D018384:Oxidative Stress
chemical_list: D019380:Anti-HIV Agents; D028441:F2-Isoprostanes; D016877:Oxidants